Two genes that are significantly influenced by CHCHD6 deficiency are hmgcr and cyp46a1. This further underscores CHCHD6 as a potential therapeutic target of AD, the manipulation of which acts on cholesterol biosynthesis and elimination simultaneously. This evidence concerns the gene CYP46A1 and Alzheimer disease.